louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04491825: Diagnostic Classifier for Cutaneous T-cell Lymphomas
Official title: Diagnostic Classifier for Cutaneous T-cell Lymphomas
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: CTCL/ Mycosis Fungoides
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2020-07-29
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: MF patients need prior histopathological verification of their disease.

Eczema and psoriasis patients will be diagnosed clinically and, if necessary, on a histopathological basis.

Brief summary: Primary cutaneous T-cell lymphomas (CTCL) are a form of skin cancer that is derived from immune cells. The most common form of CTCL is mycosis fungoides (MF). While initially confined to the skin, MF may spread to lymph nodes, blood or inner organs, resulting in an overall poor prognosis for the patient. Thus, being a potentially lethal disease, an early and correct diagnosis of MF has very important implications for the patient. However, diagnosis of early MF is often difficult, as it usually shows a close resemblance to benign inflammatory conditions such as eczema and psoriasis. Strikingly, it takes an average of 3-6 (!) years from the appearance of the first skin lesions until a diagnosis of MF can be made. For this reason, a test to distinguishing early MF from benign inflammatory conditions is urgently mandated. By using skin suction blister fluid as well as skin biopsies from patients with MF, eczema and psoriasis, the investigators want to develop a classifier system that can distinguish early MF from benign inflammatory skin diseases.


Eligibility criteria: Inclusion Criteria:

* Clinical and/or histopathological diagnosis of MF, eczema or psoriasis
* Healthy control subjects without personal history of MF, eczema or psoriasis

Exclusion Criteria:

* Ongoing skin-targeted treatment (Wash out times: 2 weeks for topical, and 4 weeks for systemic treatments)
* Ongoing other treatment that might, in the opinion of the investigator, influence proteomic features of the samples to be acquired

Primary outcomes:
measure: Proteomic signature of MF in comparison to eczema, psoriasis, and healthy control skin
timeFrame: At baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna
Study officials:
References:
Clinical trial NCT01752725: Comparison of BiCision® Versus UltraCision® During Laparoscopic Supracervical Hysterectomy (LASH)
Official title: Comparison of BiCision® Versus UltraCision® During Laparoscopic Supracervical Hysterectomy (LASH): A Prospective, Controlled, Randomized, Non-inferiority in Vivo Human Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Uterine Bleeding Disorders
Benign Uterine Conditions
Focus: Comparison of Two Instruments
Keywords: supracervical hysterectomy
vessel sealing
bipolar electrocoagulation
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
Collaborators: name: Erbe Elektromedizin GmbH
First posted: 2012-12-19
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is the evaluation of the efficiency and safety of the new, CE-certified thermofu-sion and dissection instrument BiCision® in comparison with the long established Ultracision® Har-monic Scalpel(Ethicon)during a laparoscopic supracervical hysterectomy (LASH).


Eligibility criteria: Inclusion Criteria:

* age \> 18
* gender: female
* indication for laparoscopic supracervical hysterectomy with no adnexectomyor other surgery
* will and the capability to comply the study requirements
* signed informed consent

Exclusion Criteria:

* Invasive malignome in the pelvis
* Cardiac pacemaker or implanted defibrilator if no informations are available about the compatibil-ity with RF energy
* Abnormal blood parameters (values less than factor 0.8 or more than 1.25 compared to the val-ues of creatinine and standard hemogram)
* Abnormal coagulation parameters: PTT \> 40 sec. and / or Quick's-Value\< 50% (the use of antiplateletsup to a max. of 100mg/d is no exclusion criteria)
* Inability to understand the purpose of the study
* status after a laparotomy by a longitudinal incision
* intraabdominal adhesions (at the beginning of the surgery ≥ 5 sectioning for adhesiolysis)
* open laparoscopy required
* different anatomical situations that yields to different surgery requirements
* conspicuous PAP, cervixmyoma or endometriosis of the rectovaginale space

Primary outcomes:
measure: Operation time
timeFrame: Participants will be followed for the duration of hospital stay, an expexted average of 8 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tübingen
country: Germany
facility: University Hospital
Study officials:
affiliation: University Hospital Tuebingen
name: Diethelm Wallwiener, Professor
role: STUDY_CHAIR
affiliation: University Hospital Tuebingen
name: Bernhard Krämer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03122925: TCA Cycle in the Dentate in Friedreich's Ataxia
Official title: Measurement of the TCA Cycle Rate in the Dentate Nucleus in Friedreich's Ataxia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Friedreich Ataxia
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2017-04-21
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy controls Friedreich's Ataxia diagnosis

Brief summary: OBJECTIVE: To measure the tricarboxylic acid (TCA) cycle rate in the dentate nucleus in a group of control subjects and subjects with Friedreich's Ataxia (FRDA).

HYPOTHESIS: The TCA cycle rate will be lower in FRDA subjects than in controls APPROACH: The investigators will infuse carbon-13 (13C) labeled glucose and measure the rate of 13C label incorporation from glucose to glutamate in the brain using in vivo magnetic resonance spectroscopy.

Detailed description: The investigators will measure the TCA cycle rate in the dentate nucleus in a group of FRDA patients and in a group of age-matched healthy controls using 13C MRS in vivo together with systemic i.v. infusion of 13C-labeled glucose.

The investigators aim to obtain adequate data in 16 subjects grouped as follows:

* n=4 pilot subjects (healthy subjects) for testing and optimization of the experimental setup.
* n=6 healthy controls
* n=6 FRDA patients

In other to reach this goal, the investigators plan to recruit up to 20 subjects, in case some subjects withdraw before completion of the MR scan, or in case the measured data are not adequate (e.g. technical problem with the scanner).

Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* able to consent for themselves
* considered healthy (controls) OR be diagnosed with FRDA.

Exclusion Criteria:

* All subjects:
* Participants who cannot have an MRI, as determined by the CMRR safety screening form (e.g. metal implant)
* Pregnancy
* Clautrophobia
* Diabetes
* Clinically significant cardiac disease

Control subjects:

- Neurological disease

Primary outcomes:
measure: TCA cycle rate in the dentate nucleus
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: CMRR
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Pierre-Gilles Henry, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00433225: Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Macula Thickening
Lead sponsor: Innovative Medical
Sponsor class: INDUSTRY
First posted: 2007-02-09
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study was to evaluate the efficacy of ketorolac 0.4% on quality of vision and macula thickening in patients undergoing cataract surgery using the ReStor® multifocal IOL.


Eligibility criteria: Inclusion Criteria:

* Males or females \> 50 years old
* Scheduled to undergo bilateral phacoemulsification with implantation of a multifocal IOL.
* Likely to complete all study visits and able to provide informed consent
* Visual potential of 20/25 or better

Exclusion Criteria:

* · Prior use of topical ketorolac

  * Known contraindications to any study medication or ingredients
  * Active ocular diseases or uncontrolled systemic disease
  * Active ocular allergies

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Rockville Centre
country: United States
facility: Ophthalmic Consultants of Long Island
state: New York
Study officials:
affiliation: Ophthalmic Consultants of Long Island
name: Eric Donnenfeld
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01729325: Prevention of Post-Traumatic Stress Disorder in Soldiers
Official title: Prevention of Post-Traumatic Stress Disorder in Relation to Appetitive Aggression in Burundian Soldiers Deployed in a Peace-keeping Mission in Somalia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Post-traumatic Stress Disorder (PTSD)
Aggressive Behavior
Keywords: Post-traumatic Stress disorder (PTSD)
Aggressive Behavior
Appetitive Aggression
Resilience
Preventive Narrative Exposure Therapy
Lead sponsor: University of Konstanz
Sponsor class: OTHER
Collaborators: name: The Volkswagen Foundation
First posted: 2012-11-20
Enrollment: 118
Sex: MALE
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Soldiers in conflict or former conflict regions deployed in peace-keeping missions were and are often exposed to multiple traumatic events and situations in which they are forced to engage in violent behavior. The Preventive Narrative Exposure Therapy (Pre-NET) aims to reinforce resilience thereby reducing the risk of developing or aggravating PTSD or other mental disorders as a result of traumatic experiences. The effective prevention of mental disorders as a result of war deployment is expected to facilitate reintegration in civil life after deployment and reduce uncontrolled violence.


Eligibility criteria: Inclusion Criteria:

* Exposure to traumatic experiences derived from expert interviews with scores of the Traumatic Life Event List for War and Torture
* Soldiers are part of the Burundian army and of the joint African Union and United Nations peacekeeping mission in Somalia (AMISOM)

Exclusion Criteria:

* Current use of mind altering drugs
* Psychotic symptoms

Primary outcomes:
measure: Severity of traumatic symptoms measured via the Post-traumatic Stress Disorder Scale-Interview (PSS-I)
timeFrame: 15 months
measure: Extend of appetitive aggression via the Appetitive Aggressions Scale (AAS)
timeFrame: 15 months
Secondary outcomes:
measure: Severity of depressive symptoms measured via the Patient Health Questionnaire-9 (PHQ-9)
timeFrame: 15 months
measure: Strength of suicidal ideation measured via the MINI
timeFrame: 15 months
measure: Physical health complains
timeFrame: 15 months
Other outcomes:
Locations:
city: Bujumbura
country: Burundi
facility: Burundian Army (FDN)
Study officials:
References:
Clinical trial NCT02742025: Effect of an Educational and Explanatory Program for a Surgical Act on Preoperative Anxiety
Official title: Evaluation of the Effect of an Educational and Explanatory Program for a Surgical Act Provided to the Patient Prior to Said Act on Preoperative Anxiety - a Pilot Study at the Nîmes University Hospital on Elective Coronary Angiography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Preoperative Anxiety
Keywords: Coronary Angiography
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2016-04-18
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The main objective of this study is to evaluate the impact on preoperative anxiety of an education and information program conducted prior to non-urgent coronary angiography performed in patients hospitalized at the Nîmes University Hospital.

Detailed description: The secondary objectives of this study are to assess the impact of the HEARTLINK program on the following parameters:

A. Duration of hospital stay; B. Per operative blood and heart rate?; C. Patient satisfaction (visual analog scale).

Eligibility criteria: Inclusion Criteria:

* The patient must have given his/her informed and signed consent
* The patient must be insured or beneficiary of a health insurance plan
* Patient for whom elective coronary angiography is indicated
* The patient has never had a coronary angiography before

Exclusion Criteria:

* The patient is participating in another study
* The patient is in an exclusion period determined by a previous study
* The patient is under judicial protection, under tutorship or curatorship
* The patient refuses to sign the consent
* It is impossible to correctly inform the patient
* The patient is pregnant or breastfeeding
* The subject has already had a coronary angiography
* The subject has a cognitive impairment

Primary outcomes:
measure: Amsterdam Preoperative Anxiety and Information Scale (APAIS)
timeFrame: Day 0 (within 1 hour preceding a coronography)
Secondary outcomes:
measure: Duration of hospitalization
timeFrame: Date hospital discharge (expected maximum of 5 days)
measure: Blood pressure
timeFrame: Day 0 (within 1 hour preceding a coronography)
measure: Cardiac frequency (beats per minute)
timeFrame: Day 0 (within 1 hour preceding a coronography)
measure: Visual analog scale for satisfaction concerning care
timeFrame: Day 0 (within 1 hour preceding a coronography)
Other outcomes:
Locations:
city: Nîmes Cedex 09
country: France
facility: CHRU de Nîmes - Hôpital Universitaire Carémeau
Study officials:
affiliation: Centre Hospitalier Universitaire de Nîmes
name: Eric Baljou, IDE
role: STUDY_DIRECTOR
References:
Clinical trial NCT02125825: Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Titration
Official title: Kinesia-D Phase II In-Clinic Continuous Assessment Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson's Disease
Lead sponsor: Great Lakes NeuroTechnologies Inc.
Sponsor class: INDUSTRY
Collaborators: name: National Institute on Aging (NIA)
name: University of Rochester
name: Johns Hopkins University
First posted: 2014-04-29
Enrollment: 14
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals with Parkinson's disease and a history of levodopa-induced dyskinesia

Brief summary: The objective is to assess a compact, portable, wireless movement disorder system with continuous monitoring capabilities to detect and quantify the severity of levodopa-induced dyskinesia in Parkinson's disease.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of idiopathic Parkinson's disease
* Clinical history of levodopa-induced dyskinesia
* 21 Years of age or older
* Stage 2 - 4 OFF-medication on the Hoehn and Yahr scale

Exclusion Criteria:

* Dementia (determined by a neuropsychological assessment)
* Severe tremor unaffected by levodopa

Primary outcomes:
measure: Correlation between motion sensor features and clinician-rated dyskinesia severity
timeFrame: All data will be collected within a single session not to exceed 3 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins Medical Center
state: Maryland
city: Rochester
country: United States
facility: University of Rochester Medical Center
state: New York
Study officials:
References:
Clinical trial NCT00528125: Laser Acupuncture for Pain Prevention in Neonates
Official title: Laser Acupuncture for Pain Prevention in Neonates Undergoing Heel Prick. A Prospective, Randomized, Double-blinded Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Keywords: pain prevention
neonatal pain
laser acupuncture
complementary and alternative medicine
Lead sponsor: University Children Hospital Homburg
Sponsor class: OTHER
First posted: 2007-09-12
Enrollment: 50
Sex: ALL
Minimum age (years): 1
Maximum age (years): 28
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Pain prevention and/or therapy in neonates is still a challenge. It is widely accepted that early pain experience can have a tremendous impact on the pain memory. We want to investigate if a simple, fast method, that is nearly devoid of side effects can lead to a significant alleviation of pain sensation in neonates. Acupuncture has been shown to be effective in various painful conditions. Trials on acupuncture in children are rare. Trials on acupuncture in neonates are lacking so far. Our hypothesis is that neonates in the active laser group experience less pain than those in the placebo group.


Eligibility criteria: Inclusion Criteria:

* Neonates with no obvious underlying disease (genetic (e.g. M. Down), metabolic)and not under pain medication

Exclusion Criteria:

* Older than 28 days

Primary outcomes:
measure: The Pain score Premature Infant Pain Profile (PIPP), according to video analysis
timeFrame: 5 minutes from the heel prick
Secondary outcomes:
measure: Cry Time
timeFrame: right after after heel prick up to 5 minutes
Other outcomes:
Locations:
city: Homburg
country: Germany
facility: University Children Hospital Homburg
state: Saarland
Study officials:
affiliation: University Children Hospital Homburg, Germany
name: Sven Gottschling, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Children Hospital Homburg, Germany
name: Ludwig Gortner, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00326625: Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
Official title: A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate Injection in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Amyotrophic Lateral Sclerosis
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sponsor class: INDUSTRY
First posted: 2006-05-17
Enrollment: 366
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under the skin, for the treatment of ALS. The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the treatment of relapsing-remitting multiple sclerosis. GA is an immunomodulating drug that has anti inflammatory and neuroprotective properties, which are believed to be of therapeutic value in ALS. The study treatment duration is 1 year (52 weeks).


Eligibility criteria: Inclusion Criteria:

1. Diagnosis of definite or probable ALS in accordance with the El-Escorial criteria.
2. Subject has experienced his/her first ALS symptoms within 3 years prior to the screening visit.
3. Slow VC test equal or greater than 70% of the predicted value.
4. The sum of the 3 respiratory items on the ALSFRS-R must total at least 10 points.
5. Stable dose of riluzole for at least 8 weeks prior to screening.
6. Age - 18-70 (inclusive).

Exclusion Criteria:

1. The use of invasive or non-invasive ventilation.
2. Subject having undergone gastrostomy.
3. Subject with any clinically significant or unstable medical condition.
4. Subjects participating in any other clinical trial (within 12 weeks prior to screening and thereafter).
5. Additional criteria per protocol.

Primary outcomes:
measure: Slope of Change From Baseline in the ALS Functional Rating Scale (ALSFRS-R)
timeFrame: Baseline, Weeks 4, 8, 12, 17, 22, 26, 31, 36, 40, 44, 48, 52
Secondary outcomes:
measure: Time to Event: Death, Tracheostomy, Permanent Assisted Ventilation
timeFrame: Baseline up to 52 weeks
Other outcomes:
Locations:
city: Haarlem
country: Belgium
facility: Teva Benelux
city: Leuven
country: Belgium
facility: Teva Benelux
city: Paris
country: France
facility: Teva France
city: Moerfelden-Walldorf
country: Germany
facility: Teva Germany
city: Morfelden-Walldorf
country: Germany
facility: Teva Germany
city: Tel Aviv
country: Israel
facility: Teva Israel
city: Milano
country: Italy
facility: Teva Italy
city: Aylesbury
country: United Kingdom
facility: Teva UK
Study officials:
affiliation: Teva Pharmaceuticals Industries LTD
name: Merav Bassan, PhD.
role: STUDY_CHAIR
References:
Clinical trial NCT05966025: Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
Official title: Evaluation of the Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Fatty Liver Disease
Fatty Liver
Keywords: Itopride in Mafld
Lead sponsor: October 6 University
Sponsor class: OTHER
Collaborators: name: Beni-Suef University
First posted: 2023-07-28
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD

Detailed description: the study will evaluate the possible benefits of itopride when added to pateints with metabolic associated fatty liver disease

Eligibility criteria: Inclusion Criteria:

* Patients presented to hepatology clinic . -Patients are diagnosed by ultrasonography and laboratory tests for liver and lipids. - -
* Patients with comorbidites like hypertension,diabetes,dyslipidemia

Exclusion Criteria:

* Exclusion criteria included the presence of liver disease due to any of the following: viral hepatitis (HBV, HCV)
* acute systemic disease
* cystic fibrosis, coeliac disease
* suspicion of muscular dystrophy, alpha-1-antitrypsin deficiency
* metabolic inherited diseases
* autoimmune hepatitis, drug toxicity and drugs known to induce steatosis (e.g. valproate, amiodarone orprednisone).
* Patients were also excluded if body weight and carbohydrate metabolism were altered by the use of parenteral nutrition
* protein malnutrition
* previous gastrointestinal surgery
* structural abnormalitiesof the gastrointestinal tract or neurological impairment.
* the use of nonsteroidal anti-inflammatory drugs,antibiotics,sglt2,dpp4,statins,glp1
* probiotics or anti-secretory drugs capable of causing achlorhydria within 2 months preceding enrolmentwere also considered exclusion criteria.
* Patient with age below 18 or above 60

Primary outcomes:
measure: incidence of MAFLD
timeFrame: "1 Year "
Secondary outcomes:
measure: Incidence of mafld
timeFrame: " 1 Year"
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Maha Youssif Fekry
Study officials:
affiliation: Beni-suaf university
name: Hoda m rabea, A Professor
role: PRINCIPAL_INVESTIGATOR
affiliation: Beni-suaf university
name: Yasmine m madney, Lecturer
role: PRINCIPAL_INVESTIGATOR
References: